Data completeness
3/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYKADIA (ceritinib) is an oral tyrosine kinase inhibitor approved by the FDA in March 2019 for the treatment of ALK-positive non-small cell lung cancer. It works by blocking anaplastic lymphoma kinase (ALK), a protein that drives cancer cell growth in patients with specific genetic mutations.
$4MPart D
PeakStable
11.1 years to LOEZYKADIA is at peak commercial stage with modest Part D spending, suggesting stable but limited volume opportunity and a mature, potentially right-sized brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZYKADIA at Novartis represents a stable, peak-stage oncology product with 11+ years of patent protection, positioning it as a reliable platform for brand management and commercial roles. However, limited clinical development and modest commercial scale (Part D: $4M) suggest this is a focused, specialized team rather than a high-growth career acceleration vehicle.
Brand Manager
Worked on ZYKADIA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.